Pipeline
Deucrictibant is the only oral B2-receptor antagonist currently in clinical development, to our knowledge.
Pharvaris has a platform of novel, potent and selective B2-receptor antagonist small molecules for the treatment of bradykinin-mediated diseases. Pharvaris’ pipeline consists of investigational therapies that are designed to treat hereditary angioedema (HAE).
Deucrictibant*
HAE
Solution
HAE
On-demandPHVS416
(immediate-release capsule)HAE
ProphylaxisPHVS719
(extended-release tablet)
PHAXXX
Undisclosed
*The FDA has placed a hold on clinical trials of deucrictibant for long-term prophylaxis in the U.S.; see our recent press releases and corporate presentation for an update on our clinical programs
Treatment Strategy
During the shared decision process, people living with HAE and their treating physicians, may opt for treatment of attacks (on-demand treatment) or may prefer to prevent attacks (prophylactic treatment) based on clinical assessment and personal choice.
By bringing the promise of both these new treatment options to people living with HAE, Pharvaris aims to enable those with HAE to have fewer disruptions in their daily activities, resulting in an improved quality of life.
Product Summary
PHVS416 (deucrictibant immediate-release capsule)
- Rapid exposure
- Effective manifestation mitigation
Rapidly reaches therapeutic exposure within 30 minutes, making it optimally formulated for on-demand treatment of attacks. Its rapid* onset, one-dose symptom resolution, and oral delivery1 aims to fulfill an unmet need of people living with HAE.**
*Subjective
**Aspirational, to be confirmed with clinical data
PHVS719 (deucrictibant extended-release tablet)
- Sustained attack prevention
Maintains sustained therapeutic exposure for over 24 hours, allowing for once-daily administration to prevent HAE attacks. It is designed to significantly reduce HAE attack frequency.**
**Aspirational, to be confirmed with clinical data
Deucrictibant
Deucrictibant* is the only oral B2-receptor antagonist currently in clinical development. Our aim is to develop distinct, optimized formulations for both acute treatment, through rapid onset of activity, and preventive treatment, through prolonged efficacy, of HAE.
*The FDA has placed a hold on the clinical trials of deucrictibant for long-term prophylaxis in the U.S.
